Ovid Therapeutics (OVID) Non Operating Income (2016 - 2026)
Ovid Therapeutics (OVID) reported Non Operating Income of $858000.0 for Q1 2026, down 62.94% on a YoY basis from $2.3 million in Q1 2025, and down 96.09% quarter-over-quarter from $22.0 million in Q4 2025.
Ovid Therapeutics (OVID) Non Operating Income (2016 - 2026) Analysis & Trends
Ovid Therapeutics has reported Non Operating Income for 10 years, with the latest figure at $858000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 62.94% year-over-year to $858000.0; the trailing twelve-month figure through Mar 2026 stood at $23.6 million (down 26.44% YoY), and the FY2025 full-year result was $25.0 million, down 29.41% from the prior year.
- Non Operating Income for Q1 2026 stood at $858000.0, down from $22.0 million in the prior quarter.
- The five-year high for Non Operating Income was $29.0 million in Q2 2024, with the low at -$780000.0 in Q3 2024.
- Historically, Non Operating Income has averaged $4.1 million across 5 years, with a median of $858000.0 in 2026.
- The largest YoY upside for Non Operating Income was 1546.15% in 2024 against a maximum downside of 200.52% in 2024.
- Ovid Therapeutics' Non Operating Income stood at $668123.0 in 2022, then soared by 329.11% to $2.9 million in 2023, then tumbled by 48.76% to $1.5 million in 2024, then soared by 1394.69% to $22.0 million in 2025, then tumbled by 96.09% to $858000.0 in 2026.
- The last three Non Operating Income figures came in at $858000.0 (Q1 2026), $22.0 million (Q4 2025), and $365000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | 858,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 858,000.00 |
| Dec 31, 2025 | 21.96 Mn |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 389,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | -780,000.00 |
| Jun 30, 2024 | 29.04 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Sep 30, 2023 | 776,000.00 |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 668,123.00 |
| Sep 30, 2022 | 836,085.00 |
| Jun 30, 2022 | -284,127.00 |
| Mar 31, 2022 | 209,050.00 |
| Jun 30, 2020 | 590,491.00 |
| Mar 31, 2020 | 264,296.00 |
| Dec 31, 2019 | 299,000.00 |